Loading clinical trials...
Loading clinical trials...
A Phase IIb, Long-Term Extension Study to Evaluate the Safety and Efficacy of HB0034 in the Treatment of Adult Subjects With Generalized Pustular Psoriasis
This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).
This study will also evaluate the pharmacokinetic (PK) profile of HB0034 and explore the immunogenicity of HB0034 in subjects with GPP
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Peking University People's Hospital (PKUPH)
Beijing, China
Peking University People's Hospital
Beijing, China
The Second affiliated Hospital zhejiang University School of Medicine
Hangzhou, China
Start Date
September 2, 2024
Primary Completion Date
December 30, 2025
Completion Date
June 30, 2026
Last Updated
February 14, 2025
33
ESTIMATED participants
HB0034
DRUG
Lead Sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
NCT06323356
NCT07448428
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06886009